Daraxonrasib is a once-a-day pill that targets the faulty gene behind more than nine in ten pancreatic cancers. In the largest research trial so far it roughly doubled survival for people whose cancer had already spread, and results presented in November 2026 showed tumours shrinking in six in ten newly diagnosed patients. It is approved in the US and the EU, but it is not yet licensed in the UK, where it is available only through clinical research trials.
Medically reviewed by Dr Jay Dadhania, Medical Oncologist
It arrives in a year of real progress in cancer, from multi-cancer blood tests to new targeted drugs, against a backdrop of UK cancer survival rates that still trail many comparable countries. Here is what the headlines got right, what they left out, and what it means if you or someone you love is affected.
At a glance
- A daily tablet that blocks the faulty RAS proteins driving most pancreatic cancers
- In a 500-person research trial, half of patients lived 13.2 months or more, against 6.7 months on chemotherapy
- Given with chemotherapy as a first treatment, it stopped tumours growing in 90% of 61 patients
- Serious side effects were less common than with chemotherapy, although skin rash is very common
- Not licensed in the UK; access is through research trials only
- It is not a cure, and most patients eventually stop responding
What is daraxonrasib and how does it work?
Daraxonrasib is a targeted cancer drug taken as a 300 mg tablet once a day. It is not chemotherapy, and it is not immunotherapy.
Most pancreatic cancers are driven by a fault in a gene called KRAS, part of a family of genes known as RAS. When KRAS is faulty it stays switched on, constantly telling cancer cells to grow. For four decades scientists called it "undruggable".
Earlier drugs of this type each blocked only one specific KRAS fault. Daraxonrasib works differently: it locks onto the switched-on form of several RAS proteins at once, which is why it can work across the many different faults seen in pancreatic cancer. More than nine in ten patients in the main trial had one of these faults.
What did the daraxonrasib trials show?
Much of the news coverage has blended two different trials. They answer different questions, so it helps to see them side by side.
Main research trial
Already treated, cancer has spread
- Who took part
- 500 people whose pancreatic cancer had spread and who had already had treatment
- Treatment
- The pill alone, compared with chemotherapy
- Survival
- Half lived 13.2 months or more, against 6.7 months on chemotherapy
- Tumours shrank
- 30% of patients, against 11% on chemotherapy
New combination trial
Newly diagnosed, cancer has spread
- Who took part
- 61 people newly diagnosed, followed for 18 months on average
- Treatment
- The pill plus two standard chemotherapy drugs
- Tumour control
- Tumours stopped growing in 90% and shrank in 61%
- Undetectable on scans
- About 1 in 12 patients
Sources: New England Journal of Medicine, May 2026; US Food and Drug Administration, August 2026; results presented at the EORTC-NCI-AACR symposium in Barcelona, November 2026.
The main trial was large and randomised, the most reliable kind of evidence. The combination trial was smaller and early-stage, with no comparison group. Even so, 76.6% of its patients were alive a year after starting treatment. Around 40 to 45% of patients usually survive a year on chemotherapy alone, although that figure comes from earlier studies rather than a direct comparison within this trial.
Is daraxonrasib a cure for pancreatic cancer?
No, and the doctors involved are clear about that. The excitement is about time: for a cancer where half of people die within three months of diagnosis, a treatment that can double survival, often with fewer of the burdens of chemotherapy, is a significant step.
"Cancer can come back and even if scans show there is no sign of it, you don't necessarily know you are cancer-free until more time has passed."
Dr Sam Godfrey, Cancer Research UK, speaking to the BBC
The bigger issue is resistance. Research published in August 2026 found that most patients eventually stop responding, often after several months, as the cancer finds ways around the drug, most commonly by making extra copies of the faulty gene. One high-profile US patient, former senator Ben Sasse, reported a 76% shrinkage in his tumours in early 2026, but said by September that his cancer had become resistant. Scientists are now testing combinations designed to delay that point.
What are the side effects of daraxonrasib?
Side effects are common, but they are different from chemotherapy's. These were the most frequent in the main trial:
Source: US prescribing information, August 2026.
The important balance is this: serious side effects were less common than with chemotherapy (61.8% of patients against 69.6%), and only 1.2% stopped taking the pill because of them, against 11.2% on chemotherapy. Rarer but serious risks include a tear in the bowel wall and inflammation of the lungs, which is why patients are monitored closely.
How much does daraxonrasib cost?
In the US the list price is $39,800 for a 30-day supply, close to half a million dollars a year before insurance or discounts. There is no UK price, because the drug is not licensed here. If it is approved, the NHS price would be negotiated as part of the usual assessment.
Can you get daraxonrasib in the UK?
Not yet, except through research trials. This is how it would reach NHS patients, and where things stand.
A UK licence
The maker must apply to the Medicines and Healthcare products Regulatory Agency (MHRA), the UK's medicines regulator. In June 2026 the government confirmed it was not licensed in the UK.
NHS funding
Once licensed, the National Institute for Health and Care Excellence (NICE), which decides which treatments the NHS in England pays for, would assess its value. It was not on NICE's work programme as of June 2026.
A realistic timeline
Pancreatic Cancer UK estimates the process could take about a year once the company applies.
Research trials now
A small number of UK patients are taking part in trials, including for newly diagnosed spread cancer and after surgery. Search "daraxonrasib" on the NHS-backed Be Part of Research website.

If you or someone close to you is being treated for pancreatic cancer, the best first step is to ask the cancer team directly whether a trial could be suitable. It cannot be bought or prescribed privately in the UK while it remains unlicensed.
If you are in the US
Daraxonrasib has been approved since August 2026 for previously treated pancreatic cancer that has spread. The list price is $39,800 a month, although insured patients may pay much less through co-pay support. A US expanded access programme opened in May 2026. Speak to your oncologist about eligibility.
Why is pancreatic cancer so often found late?
Pancreatic cancer has the lowest survival of all common cancers in the UK, with around 11,500 people diagnosed and around 10,200 deaths each year, according to Cancer Research UK.
Sources: Pancreatic Cancer UK; The Guardian, November 2026.
Catching it early changes the picture: one-year survival is six times higher for people diagnosed at an early stage. The difficulty is that early pancreatic cancer often causes no symptoms, and there is no national screening programme for it in the UK. Researchers are working on new ways to find cancers sooner, from blood tests to the capsule sponge test for the food pipe.

Pancreatic cancer symptoms worth acting on
The NHS lists these possible symptoms. Most are common and usually caused by something less serious, but they are worth knowing.
Possible symptoms
- Yellow skin or whites of the eyes (jaundice), itchy skin, darker pee or paler poo
- Losing weight without trying, or loss of appetite
- Feeling tired or having no energy
- A high temperature, or feeling hot, cold or shivery
- Feeling or being sick, diarrhoea or constipation
- Pain at the top of the tummy and the back, or indigestion such as bloating
When to get help
- Ask for an urgent GP appointment or contact NHS 111 if your skin or the whites of your eyes turn yellow
- Get urgent advice if you have been sick for more than two days
- Get urgent advice if you have had diarrhoea for more than a week
- See a GP if you have lost a noticeable amount of weight
- See a GP if other symptoms have not improved after two weeks
- See a GP if your symptoms change, get worse or do not feel normal for you
Could daraxonrasib help other cancers?
Possibly. Faulty RAS genes also drive many lung and bowel cancers. A large trial in lung cancer is under way, and earlier studies are looking at bowel cancer, melanoma and others. Cancer Research UK has said the results raise the possibility of treating other cancers with the same mutations, although more trials are needed before anyone knows.
Our clients also ask
Is daraxonrasib chemotherapy?
No. It is a targeted drug that blocks the faulty proteins driving the cancer, rather than killing fast-growing cells in general as chemotherapy does. It is also not an immunotherapy. In trials it has been given both on its own and alongside chemotherapy.
How is daraxonrasib taken?
As a 300 mg tablet once a day, swallowed whole, at the same time each day, with or without food. The dose can be lowered if side effects are hard to manage.
Does daraxonrasib work?
In the main trial it roughly doubled average survival compared with chemotherapy, from 6.7 to 13.2 months, in people whose cancer had spread. It does not work for everyone, and most patients eventually stop responding.
Can daraxonrasib put pancreatic cancer into remission?
In the combination trial, the cancer became undetectable on scans in about 1 in 12 patients, and some had not seen it return after around 18 months. Doctors stress that this is not yet the same as a confirmed long-term remission, and longer follow-up is needed.
How long does daraxonrasib work for?
It varies from person to person. In the main trial the cancer was held back for 7.2 months on average before growing again, against 3.6 months on chemotherapy. Most patients eventually become resistant, which is why combinations with other treatments are being tested.
Do you need a gene test to have daraxonrasib?
Not under the US approval. Most pancreatic cancers carry a KRAS fault, and more than nine in ten patients in the main trial did, but doctors may still recommend testing to guide treatment.
When will daraxonrasib be available on the NHS?
There is no date yet. It first needs a UK licence from the MHRA and then a NICE assessment. Pancreatic Cancer UK estimates this could take about a year once the company applies.
Can I buy daraxonrasib privately in the UK?
No. Because it is not licensed in the UK, it cannot be prescribed in the usual way, privately or on the NHS. UK access is currently through research trials only.
Is daraxonrasib available in India?
No. It has not been approved in India, and Indian media have reported the US price as close to Rs 38 lakh a month.
Are we close to curing pancreatic cancer?
Not yet. But for the first time in decades a drug has meaningfully extended survival for advanced pancreatic cancer, and experts see it as the start of a new kind of treatment rather than the end of the road.
About First Health Check
Know your health before symptoms appear
There is no NHS screening programme for pancreatic cancer, and no single test can rule it out. Our Diamond and Platinum assessments include a CT scan of the abdomen that looks at the pancreas, liver and gallbladder, alongside blood tests for blood sugar and liver function. We take you from the UK to India for a thorough full body health check: three unhurried days, seen by 17 individual specialists, with a five-star hotel, private chauffeur and local sightseeing included.
First Health Check is not connected with the developer of daraxonrasib or the trials described. Details of individual patients are taken from published news reports. This article is for information only and is not medical advice; please speak to your own doctor about your health.
Sources
- New England Journal of Medicine: daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer (May 2026)
- US Food and Drug Administration: approval announcement (August 2026)
- BBC News: combination trial results (November 2026)
- UK Parliament: written answer on UK licensing (June 2026)
- Pancreatic Cancer UK: pancreatic cancer statistics
- NHS: symptoms of pancreatic cancer



